400 related articles for article (PubMed ID: 33896328)
1. Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients.
Asare JM; Rabik CA; Muller B; Brown PA; Cooper S
Expert Opin Investig Drugs; 2021 Jun; 30(6):611-620. PubMed ID: 33896328
[No Abstract] [Full Text] [Related]
2. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.
Valecha GK; Ibrahim U; Ghanem S; Asti D; Atallah JP; Terjanian T
Expert Rev Hematol; 2017 Sep; 10(9):783-799. PubMed ID: 28666090
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances in Adult Acute Lymphoblastic Leukemia.
Richard-Carpentier G; Kantarjian H; Jabbour E
Curr Hematol Malig Rep; 2019 Apr; 14(2):106-118. PubMed ID: 30879177
[TBL] [Abstract][Full Text] [Related]
4. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibodies in acute lymphoblastic leukemia therapy.
Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
[TBL] [Abstract][Full Text] [Related]
6. A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia.
Martino M; Alati C; Canale FA; Musuraca G; Martinelli G; Cerchione C
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670075
[TBL] [Abstract][Full Text] [Related]
7. Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia.
Leahy AB; Elgarten CW; Grupp SA; Maude SL; Teachey DT
Expert Rev Anticancer Ther; 2018 Oct; 18(10):959-971. PubMed ID: 30111196
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
Ribera JM
Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
[TBL] [Abstract][Full Text] [Related]
9. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
[TBL] [Abstract][Full Text] [Related]
10. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
Zhang M; Huang H
Front Immunol; 2020; 11():611710. PubMed ID: 33384696
[TBL] [Abstract][Full Text] [Related]
11. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy.
Aldoss I; Forman SJ
Blood; 2020 Mar; 135(11):804-813. PubMed ID: 31899793
[TBL] [Abstract][Full Text] [Related]
12. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
[TBL] [Abstract][Full Text] [Related]
13. Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin.
Kantarjian H; Jabbour E
Am Soc Clin Oncol Educ Book; 2018 May; 38():574-578. PubMed ID: 30231308
[TBL] [Abstract][Full Text] [Related]
14. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Frey NV; Luger SM
Blood; 2015 Jul; 126(5):589-96. PubMed ID: 25966988
[TBL] [Abstract][Full Text] [Related]
15. Are CAR T cells better than antibody or HCT therapy in B-ALL?
Pulsipher MA
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):16-24. PubMed ID: 30504287
[TBL] [Abstract][Full Text] [Related]
16. Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma.
DuVall AS; Wesevich A; Larson RA
Curr Hematol Malig Rep; 2023 Dec; 18(6):217-225. PubMed ID: 37490229
[TBL] [Abstract][Full Text] [Related]
17. CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome.
Chen L; Xu B; Long X; Gu J; Lou Y; Wang D; Cao Y; Wang N; Li C; Wang G; Wang Y; Zhu L; Wang J; An H; Xiao M; Xiao Y; Zhou J
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32345625
[TBL] [Abstract][Full Text] [Related]
18. Treatment of relapsed/refractory acute lymphoblastic leukemia.
Paul S; Rausch CR; Nasnas PE; Kantarjian H; Jabbour EJ
Clin Adv Hematol Oncol; 2019 Mar; 17(3):166-175. PubMed ID: 30969955
[TBL] [Abstract][Full Text] [Related]
19. The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia.
Horvat TZ; Seddon AN; Ogunniyi A; King AC; Buie LW; Daley RJ
Ann Pharmacother; 2018 Mar; 52(3):268-276. PubMed ID: 29025266
[TBL] [Abstract][Full Text] [Related]
20. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]